FDAFDA · Food and drugs·Recall number D-0024-2023
Buprenorphine and Naloxone Sublingual Tablets 8 mg/2 mg, 30-count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512 Manufactured by: Sun Pharmaceutical Industries Ltd. Survey No. 259/15, Dadra-396 191, (U.T. of D & NH), India; NDC 62756-970-83
Published November 9, 2022 · Recall initiated: October 18, 2022
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Presence of Foreign Substance
What to do
Voluntary: Firm initiated · Letter
Recall details
- Brand
- BUPRENORPHINE AND NALOXONE
- Manufacturer
- SUN PHARMACEUTICAL INDUSTRIES INC
- Distributor
- Nationwide with the United States
- UPC
- 0362756969834
- Lot
- Lot #: DNC1129A, Exp 06/2023 Lot #: DNC1740A, Exp 09/2023
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Sell products like this?
Recalert watches your whole catalog for recalls like this one, automatically.